NATERA INC (NTRA) Stock Fundamental Analysis
USA - NASDAQ:NTRA - US6323071042 - Common Stock
200.59 USD
-0.08 (-0.04%)
NTRA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for NTRA as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, NTRA is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
NTRA had negative earnings in the past year.
In the past year NTRA had a positive cash flow from operations.
NTRA had negative earnings in each of the past 5 years.
NTRA had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -14.41%, NTRA belongs to the top of the industry, outperforming 81.17% of the companies in the same industry.
NTRA's Return On Equity of -20.32% is amongst the best of the industry. NTRA outperforms 83.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.41% | ||
| ROE | -20.32% | ||
| ROIC | N/A |
ROA(3y)-26.97%
ROA(5y)-28.74%
ROE(3y)-50.12%
ROE(5y)-53.96%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of NTRA (62.86%) is better than 79.47% of its industry peers.
In the last couple of years the Gross Margin of NTRA has grown nicely.
NTRA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.86% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.09%
GM growth 5Y7.51%
2. Health
2.1 Basic Checks
NTRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NTRA has been increased compared to 1 year ago.
The number of shares outstanding for NTRA has been increased compared to 5 years ago.
The debt/assets ratio for NTRA has been reduced compared to a year ago.
2.2 Solvency
NTRA has an Altman-Z score of 31.45. This indicates that NTRA is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 31.45, NTRA belongs to the best of the industry, outperforming 94.92% of the companies in the same industry.
NTRA has a debt to FCF ratio of 0.77. This is a very positive value and a sign of high solvency as it would only need 0.77 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 0.77, NTRA belongs to the best of the industry, outperforming 94.35% of the companies in the same industry.
A Debt/Equity ratio of 0.06 indicates that NTRA is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.06, NTRA is not doing good in the industry: 61.96% of the companies in the same industry are doing better.
Even though the debt/equity ratio score it not favorable for NTRA, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | 0.77 | ||
| Altman-Z | 31.45 |
ROIC/WACCN/A
WACC8.67%
2.3 Liquidity
A Current Ratio of 3.72 indicates that NTRA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.72, NTRA is in line with its industry, outperforming 43.69% of the companies in the same industry.
NTRA has a Quick Ratio of 3.58. This indicates that NTRA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.58, NTRA is in line with its industry, outperforming 44.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.72 | ||
| Quick Ratio | 3.58 |
3. Growth
3.1 Past
The earnings per share for NTRA have decreased strongly by -30.11% in the last year.
Looking at the last year, NTRA shows a very strong growth in Revenue. The Revenue has grown by 38.17%.
Measured over the past years, NTRA shows a very strong growth in Revenue. The Revenue has been growing by 41.20% on average per year.
EPS 1Y (TTM)-30.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-146.15%
Revenue 1Y (TTM)38.17%
Revenue growth 3Y39.47%
Revenue growth 5Y41.2%
Sales Q2Q%34.66%
3.2 Future
NTRA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.38% yearly.
The Revenue is expected to grow by 16.62% on average over the next years. This is quite good.
EPS Next Y-32.78%
EPS Next 2Y7.14%
EPS Next 3Y29.95%
EPS Next 5Y26.38%
Revenue Next Year26.21%
Revenue Next 2Y20.7%
Revenue Next 3Y19.53%
Revenue Next 5Y16.62%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NTRA. In the last year negative earnings were reported.
Also next year NTRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Price/Free Cash Flow ratio of NTRA indicates a rather cheap valuation: NTRA is cheaper than 90.21% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 263.31 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
NTRA's earnings are expected to grow with 29.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.14%
EPS Next 3Y29.95%
5. Dividend
5.1 Amount
No dividends for NTRA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:NTRA (11/14/2025, 9:50:58 AM)
200.59
-0.08 (-0.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners93.57%
Inst Owner Change-0.17%
Ins Owners3.13%
Ins Owner Change-2.14%
Market Cap27.53B
Revenue(TTM)2.12B
Net Income(TTM)-253.24M
Analysts84.44
Price Target198.71 (-0.94%)
Short Float %2.92%
Short Ratio3.53
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.64%
Min EPS beat(2)-17.78%
Max EPS beat(2)23.06%
EPS beat(4)2
Avg EPS beat(4)14.54%
Min EPS beat(4)-17.78%
Max EPS beat(4)55.66%
EPS beat(8)6
Avg EPS beat(8)19.24%
EPS beat(12)9
Avg EPS beat(12)15.23%
EPS beat(16)11
Avg EPS beat(16)9.5%
Revenue beat(2)2
Avg Revenue beat(2)11.38%
Min Revenue beat(2)10.25%
Max Revenue beat(2)12.51%
Revenue beat(4)4
Avg Revenue beat(4)12.74%
Min Revenue beat(4)8.92%
Max Revenue beat(4)19.28%
Revenue beat(8)8
Avg Revenue beat(8)11.42%
Revenue beat(12)10
Avg Revenue beat(12)8.34%
Revenue beat(16)14
Avg Revenue beat(16)6.87%
PT rev (1m)0.38%
PT rev (3m)1.14%
EPS NQ rev (1m)1.13%
EPS NQ rev (3m)33.54%
EPS NY rev (1m)-2.9%
EPS NY rev (3m)9.45%
Revenue NQ rev (1m)-0.03%
Revenue NQ rev (3m)2.52%
Revenue NY rev (1m)1.14%
Revenue NY rev (3m)4.76%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 14.02 | ||
| P/FCF | 263.31 | ||
| P/OCF | 147.46 | ||
| P/B | 22.09 | ||
| P/tB | 22.09 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.29
EYN/A
EPS(NY)-1.3
Fwd EYN/A
FCF(TTM)0.76
FCFY0.38%
OCF(TTM)1.36
OCFY0.68%
SpS14.31
BVpS9.08
TBVpS9.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.41% | ||
| ROE | -20.32% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.86% | ||
| FCFM | 5.32% |
ROA(3y)-26.97%
ROA(5y)-28.74%
ROE(3y)-50.12%
ROE(5y)-53.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.09%
GM growth 5Y7.51%
F-Score6
Asset Turnover1.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | 0.77 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 234.12% | ||
| Cap/Sales | 4.18% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.72 | ||
| Quick Ratio | 3.58 | ||
| Altman-Z | 31.45 |
F-Score6
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)232.23%
Cap/Depr(5y)273.02%
Cap/Sales(3y)4.66%
Cap/Sales(5y)5.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-146.15%
EPS Next Y-32.78%
EPS Next 2Y7.14%
EPS Next 3Y29.95%
EPS Next 5Y26.38%
Revenue 1Y (TTM)38.17%
Revenue growth 3Y39.47%
Revenue growth 5Y41.2%
Sales Q2Q%34.66%
Revenue Next Year26.21%
Revenue Next 2Y20.7%
Revenue Next 3Y19.53%
Revenue Next 5Y16.62%
EBIT growth 1Y6.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.74%
EBIT Next 3Y44.52%
EBIT Next 5Y27.11%
FCF growth 1Y127%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y154.49%
OCF growth 3YN/A
OCF growth 5YN/A
NATERA INC / NTRA FAQ
What is the ChartMill fundamental rating of NATERA INC (NTRA) stock?
ChartMill assigns a fundamental rating of 4 / 10 to NTRA.
Can you provide the valuation status for NATERA INC?
ChartMill assigns a valuation rating of 2 / 10 to NATERA INC (NTRA). This can be considered as Overvalued.
How profitable is NATERA INC (NTRA) stock?
NATERA INC (NTRA) has a profitability rating of 3 / 10.